Noticias de PFE_US

Mercado

Noticias del mercado

Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PFE_US ✕ 665 resultados
04/09/2026 PFE_US — The Motley Fool
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

04/09/2026 PFE_US — The Globe and Mail
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

04/09/2026 PFE_US — Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

04/09/2026 PFE_US — Yahoo Finance
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company

04/09/2026 PFE_US — ad-hoc-news.de
Pfizer Inc. stock gains as updated COVID vaccine fuels valuation debate

Pfizer Inc. stock has advanced in recent weeks amid approval of an updated COVID-19 vaccine, with th

04/09/2026 PFE_US — MyChesCo
Medicus Pays $27 Million for Pfizer Cancer Drug Rights

CONSHOHOCKEN, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) agreed Wednesday to pay Pfizer Inc. $27 million for worldwide rights to an early-stage antibody-drug conjugate, taking control of CD228V’s development while …

04/09/2026 PFE_US — Kalkine Media
Why Is Pfizer (NYSE:PFE) Climbing Toward Multi-Year Highs on Vaccine and Pipeline Momentum?

Pfizer (NYSE:PFE) shares approach multi-year highs on vaccine pipeline momentum, upgraded coronavirus vaccine authorization, Lyme program progress, and raised full-year guidance.

03/09/2026 PFE_US — Yahoo Finance
Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check

Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...

03/09/2026 PFE_US — finance.biggo.com
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion

Pfizer has licensed PF-08046031, an antibody-drug conjugate targeting CD228 that it discontinued earlier this year, to Medicus Pharma in a deal worth…

03/09/2026 PFE_US — AD HOC NEWS
Pfizer Inc. stock reaches new 52-week high as investors digest earnings and dividend

Pfizer Inc. stock has climbed to a fresh 52-week high while investors weigh the latest quarterly fig

Página 30 de 34